BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19937400)

  • 1. Diffuse large B cell lymphoma of the mesentery: an unusual presentation and review of the literature.
    Salemis NS; Gourgiotis S; Tsiambas E; Karagkiouzis G; Nakos G; Karathanasis V
    J Gastrointest Cancer; 2009; 40(3-4):79-82. PubMed ID: 19937400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical resection combined with CHOP chemotherapy plus rituximab for a patient with advanced mesenteric diffuse large B cell lymphoma.
    Yamaguchi T; Takahashi H; Kagawa R; Takeda R; Sakata S; Nishizaki D; Takamatsu T; Iwasa Y
    Hepatogastroenterology; 2008; 55(84):891-4. PubMed ID: 18705290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successfully-treated mesenteric non-Hodgkin's lymphoma involving hepatic mass--a case report.
    Yamaguchi T; Takahashi H; Kagawa R; Takeda R; Sakata S; Yamamoto M; Nishizaki D; Takamatsu T; Iwasa Y
    Gan To Kagaku Ryoho; 2007 May; 34(5):783-7. PubMed ID: 17496458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature.
    Zheng SM; Zhou DJ; Chen YH; Jiang R; Wang YX; Zhang Y; Xue HL; Wang HQ; Mou D; Zeng WZ
    World J Gastroenterol; 2017 Jun; 23(24):4467-4472. PubMed ID: 28706431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary ovarian lymphoma--a rare entity.
    Afshan A; Sadaf N
    J Pak Med Assoc; 2013 Apr; 63(4):519-20. PubMed ID: 23905454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
    Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy.
    Kim KM; Yoon DH; Lee SG; Lim SN; Sug LJ; Huh J; Suh C
    J Korean Med Sci; 2009 Jun; 24(3):525-8. PubMed ID: 19543522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsed diffuse large B-cell lymphoma--10 years later.
    Jain S; Shah N; Gregory S
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):704-8. PubMed ID: 22402517
    [No Abstract]   [Full Text] [Related]  

  • 11. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02).
    Chung MJ; Cho WK; Oh D; Eom KY; Kim JH; Kim WC; Lee JH
    J Radiat Res; 2019 Oct; 60(5):677-684. PubMed ID: 31251343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary diffuse large B-cell lymphoma of the prostate: a case report and review of the literature.
    Ren M; Liu Y
    J Med Case Rep; 2021 Nov; 15(1):546. PubMed ID: 34727993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare primary extranodal lymphomas: diffuse large B-cell lymphomas of the genital tract.
    Rajnics P; Demeter J; Csomor J; Krenács L; Pajor L; Kollár B; Kertész Z; Egyed M
    Ann Hematol; 2009 Dec; 88(12):1223-8. PubMed ID: 19352660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
    Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
    J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation.
    Manabe M; Hayashi Y; Yoshii Y; Mukai S; Sakamoto E; Kanashima H; Nakao T; Hayama T; Fukushima H; Inoue T; Yamane T; Teshima H
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1733-5. PubMed ID: 23152030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.